DK1115874T3 - Alzheimer's sygdom-sekretase - Google Patents
Alzheimer's sygdom-sekretaseInfo
- Publication number
- DK1115874T3 DK1115874T3 DK99948189T DK99948189T DK1115874T3 DK 1115874 T3 DK1115874 T3 DK 1115874T3 DK 99948189 T DK99948189 T DK 99948189T DK 99948189 T DK99948189 T DK 99948189T DK 1115874 T3 DK1115874 T3 DK 1115874T3
- Authority
- DK
- Denmark
- Prior art keywords
- alzheimer
- secretase
- disease secretase
- disease
- cleaving
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10159498P | 1998-09-24 | 1998-09-24 | |
PCT/US1999/020881 WO2000017369A2 (en) | 1998-09-24 | 1999-09-23 | Alzheimer's disease secretase |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1115874T3 true DK1115874T3 (da) | 2009-04-20 |
Family
ID=22285461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99948189T DK1115874T3 (da) | 1998-09-24 | 1999-09-23 | Alzheimer's sygdom-sekretase |
Country Status (28)
Country | Link |
---|---|
US (2) | US6835565B1 (pt) |
EP (1) | EP1115874B1 (pt) |
JP (3) | JP2002526081A (pt) |
KR (8) | KR100768381B1 (pt) |
CN (4) | CN1198936C (pt) |
AT (1) | ATE420185T1 (pt) |
AU (2) | AU772812C (pt) |
BR (1) | BR9913920A (pt) |
CA (1) | CA2343004A1 (pt) |
CY (1) | CY1111006T1 (pt) |
CZ (1) | CZ2001966A3 (pt) |
DE (1) | DE69940265D1 (pt) |
DK (1) | DK1115874T3 (pt) |
EA (1) | EA009216B1 (pt) |
ES (1) | ES2318902T3 (pt) |
HK (2) | HK1042730B (pt) |
HU (1) | HUP0103838A3 (pt) |
IL (2) | IL142207A (pt) |
IS (1) | IS5905A (pt) |
NO (1) | NO20011505L (pt) |
NZ (2) | NZ527053A (pt) |
PL (1) | PL205294B1 (pt) |
PT (1) | PT1115874E (pt) |
SG (1) | SG113454A1 (pt) |
SK (1) | SK3902001A3 (pt) |
TR (3) | TR200200662T2 (pt) |
WO (1) | WO2000017369A2 (pt) |
ZA (1) | ZA200102387B (pt) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9701684D0 (en) | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
AU1726199A (en) | 1997-12-31 | 1999-07-19 | Chiron Corporation | Metastatic cancer regulated gene |
US6699671B1 (en) * | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
KR100768381B1 (ko) | 1998-09-24 | 2007-10-18 | 파마시아 앤드 업존 캄파니 엘엘씨 | 알츠하이머병 세크레타제 |
US20040234976A1 (en) * | 1998-09-24 | 2004-11-25 | Gurney Mark E. | Alzheimer's disease secretase, app substrates therefor, and uses therefor |
US7456007B1 (en) | 1998-12-31 | 2008-11-25 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
US7115410B1 (en) | 1999-02-10 | 2006-10-03 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
GB2364059B (en) | 1999-02-10 | 2004-01-14 | Elan Pharm Inc | Beta-Secretase enzyme compositions and methods |
WO2000058479A1 (en) * | 1999-03-26 | 2000-10-05 | Amgen Inc. | Beta secretase genes and polypeptides |
US6545127B1 (en) * | 1999-06-28 | 2003-04-08 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
EP1496124A1 (en) * | 1999-06-28 | 2005-01-12 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
CA2397786A1 (en) * | 1999-09-23 | 2001-04-05 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, app substrates therefor, and uses therefor |
US7514408B1 (en) | 1999-12-02 | 2009-04-07 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
US6686449B2 (en) | 2000-06-30 | 2004-02-03 | Pharmacia & Upjohn Company | Mutant presenilin 1 polypeptides |
PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
EP1666452A2 (en) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
CA2410898A1 (en) | 2000-07-19 | 2002-01-24 | Pharmacia & Upjohn Company | Substrates and assays for .beta.-secretase activity |
US20030190635A1 (en) * | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
US7806980B2 (en) | 2000-12-23 | 2010-10-05 | Elan Pharmaceuticals, Inc. | Method for crystallizing human beta secretase in complex with an inhibitor |
US7309811B2 (en) | 2001-02-23 | 2007-12-18 | Elan Pharmaceuticals, Inc | Transgenic mice knockouts of BACE-1 |
US7524668B1 (en) | 2001-05-10 | 2009-04-28 | Elan Pharmaceuticals, Inc. | Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
IL159015A0 (en) | 2001-05-25 | 2004-05-12 | Genset Sa | Polypeptides, their preparation and use |
CA2448834A1 (en) | 2001-06-01 | 2002-12-12 | Elan Pharmaceuticals, Inc. | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases |
US20050130941A1 (en) * | 2001-06-08 | 2005-06-16 | Heinrich Schostarez | Methods of treating alzheimer's disease |
WO2002100818A2 (en) | 2001-06-13 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Aminediols as agents for the treatment of alzheimer's disease |
CA2453451A1 (en) | 2001-07-10 | 2003-01-23 | Elan Pharmaceuticals, Inc. | Aminediols for the treatment of alzheimer's disease |
MXPA04000328A (es) | 2001-07-10 | 2004-07-23 | Pharmacia & Upjohn Comapny | Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. |
MXPA04000338A (es) | 2001-07-10 | 2004-07-23 | Upjohn Co | Diamindioles para tratamiento de enfermedad de alzheimer. |
US7186539B1 (en) | 2001-08-31 | 2007-03-06 | Pharmacia & Upjohn Company | Method for refolding enzymes |
AU2002343483A1 (en) | 2001-10-04 | 2003-04-14 | Elan Pharmaceuticals, Inc. | Hydroxypropylamines |
JP4547152B2 (ja) | 2001-10-23 | 2010-09-22 | オクラホマ メディカル リサーチ ファウンデーション | β−セクレターゼ阻害剤および使用方法 |
AR039555A1 (es) | 2001-11-08 | 2005-02-23 | Upjohn Co | Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano |
MXPA04004903A (es) * | 2001-11-21 | 2005-06-06 | Elan Pharm Inc | Derivados de aminoacido utiles para el tratamiento de la enfermedad de alzheimer. |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7273743B2 (en) | 2002-02-21 | 2007-09-25 | Elan Pharmaceuticals, Inc. | Modified BACE |
AU2003303141A1 (en) | 2002-04-30 | 2004-07-22 | Elan Pharmaceuticals, Inc. | Hydroxypropyl amides for the treatment of alzheimer's disease |
US7442537B1 (en) | 2002-05-10 | 2008-10-28 | Elan Pharmaceuticals, Inc. | Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US7956176B2 (en) | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
UY27967A1 (es) | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
CA2507484A1 (en) | 2002-11-27 | 2004-06-17 | Elan Pharmaceuticals, Inc. | Substituted ureas and carbamates |
US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
CL2004000849A1 (es) | 2003-04-21 | 2005-01-28 | Elan Pharmaceuticals Inc Pharm | Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras. |
WO2004099402A1 (en) | 2003-05-02 | 2004-11-18 | Elan Pharmaceuticals, Inc. | Glycosylation variants of bace |
WO2005087751A2 (en) | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamine aspartyl protease inhibitors |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
CA2573138A1 (en) | 2004-07-09 | 2006-01-26 | Elan Pharmaceuticals Inc. | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors |
WO2006010094A1 (en) | 2004-07-09 | 2006-01-26 | Elan Pharmaceuticals, Inc. | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors |
CA2589860A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
JP5066514B2 (ja) * | 2005-03-14 | 2012-11-07 | ハイ ポイント ファーマシューティカルズ,エルエルシー | ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法 |
EP1746092A1 (en) | 2005-07-22 | 2007-01-24 | Exonhit Therapeutics SA | Compounds and methods for treatment of amyloid-B-peptide related disorders |
WO2007047305A1 (en) | 2005-10-12 | 2007-04-26 | Elan Pharmaceuticals, Inc. | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors |
US7745484B2 (en) | 2005-11-21 | 2010-06-29 | Amgen Inc. | Beta-secretase modulators and methods of use |
US7872009B2 (en) | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
US7838676B2 (en) | 2005-11-21 | 2010-11-23 | Amgen Inc. | Beta-secretase modulators and methods of use |
US20070292895A1 (en) * | 2006-05-19 | 2007-12-20 | Xiao-Ping Shi | Assays and methods to detect beta-secretase and its activity in body fluids and tissue extracts |
ATE523788T1 (de) * | 2006-06-08 | 2011-09-15 | Fu Berlin | ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN |
TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
MX2009012608A (es) | 2007-05-25 | 2009-12-07 | Amgen Inc | Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso. |
TW200901991A (en) | 2007-05-25 | 2009-01-16 | Amgen Inc | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
WO2009007300A2 (en) | 2007-07-06 | 2009-01-15 | Boehringer Ingelheim International Gmbh | Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture |
US7803809B2 (en) | 2008-11-12 | 2010-09-28 | Amgen Inc. | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use |
ES2459195T3 (es) * | 2008-09-11 | 2014-05-08 | Amgen Inc. | Compuestos de anillo espiro-tetracíclico como moduladores de beta-secretasa y métodos de uso |
TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
EP2281824A1 (en) | 2009-08-07 | 2011-02-09 | Noscira, S.A. | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
EP2504315A1 (en) | 2009-11-23 | 2012-10-03 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
US8822485B2 (en) | 2009-11-23 | 2014-09-02 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
US8735384B2 (en) | 2010-01-19 | 2014-05-27 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
EP2547685A1 (en) | 2010-03-15 | 2013-01-23 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta - secretase modulators |
JP5584352B2 (ja) | 2010-03-15 | 2014-09-03 | アムジエン・インコーポレーテツド | β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途 |
EP2601197B1 (en) | 2010-08-05 | 2014-06-25 | Amgen Inc. | Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use |
WO2012024616A1 (en) | 2010-08-19 | 2012-02-23 | Buck Institute For Age Research | Methods of treating miild cognitive impairment (mci) and related discorders |
EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
EP2643299B1 (en) | 2010-11-22 | 2016-06-22 | Noscira, S.A. | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions |
WO2012071279A1 (en) | 2010-11-23 | 2012-05-31 | Amgen Inc. | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use |
WO2012109165A1 (en) | 2011-02-07 | 2012-08-16 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use |
WO2012112462A1 (en) | 2011-02-15 | 2012-08-23 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
US9296759B2 (en) | 2011-09-21 | 2016-03-29 | Amgen Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
KR102073578B1 (ko) | 2012-03-19 | 2020-02-05 | 버크 인스티튜트 포 리서치 온 에이징 | App 특이적 bace 억제제(asbi) 및 이의 용도 |
US9556135B2 (en) | 2012-10-12 | 2017-01-31 | Amgen, Inc. | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
WO2014078314A1 (en) | 2012-11-15 | 2014-05-22 | Amgen Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
WO2014120658A1 (en) | 2013-01-29 | 2014-08-07 | Amgen Inc. | Fused multicyclic 3-amino-5,6-dihydro-2h-1,4-thiazine derivatives and their use as beta-secretase inhibitors |
EP2956443B1 (en) | 2013-02-12 | 2019-09-25 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
TW201446758A (zh) | 2013-03-01 | 2014-12-16 | Amgen Inc | 作爲β-分泌酶抑制劑的全氟化5,6-二氫-4H-1,3-□-2-胺化合物及其用途 |
KR20150124985A (ko) | 2013-03-08 | 2015-11-06 | 암젠 인크 | 베타-세크레타제 억제제로서 퍼플루오르화된 사이클로프로필 융합된 1,3-옥사진-2-아민 화합물 및 그의 사용 방법 |
US9096615B2 (en) | 2013-07-30 | 2015-08-04 | Amgen Inc. | Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof |
KR101791296B1 (ko) | 2014-04-17 | 2017-10-27 | 제주대학교 산학협력단 | 알츠하이머병 관련 돌연변이 유전자를 포함하는 발현 카세트, 벡터, 및 이를 이용하여 형질전환된 세포주 |
CN106795147B (zh) | 2014-08-08 | 2020-09-22 | 美国安进公司 | 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法 |
AU2015392754B2 (en) * | 2015-04-30 | 2019-03-14 | Jiangsu Nuo-Beta Pharmaceutical Technology Co., Ltd. | Method for screening drug and therapeutic target used for treating Alzheimer's disease |
US10246429B2 (en) | 2015-08-06 | 2019-04-02 | Amgen Inc. | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
KR20180090778A (ko) | 2015-08-27 | 2018-08-13 | 난트뉴로, 엘엘씨 | App-선택적 bace 억제를 위한 조성물 및 그의 용도 |
CA3024067C (en) | 2016-05-12 | 2024-04-09 | Buck Institute For Research On Aging | Compounds to promote normal processing of app |
MX2019007104A (es) | 2016-12-15 | 2019-11-05 | Amgen Inc | Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso. |
EP3555085B1 (en) | 2016-12-15 | 2020-12-02 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
CA3047285A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
MA54100A (fr) | 2016-12-15 | 2021-10-20 | Amgen Inc | Dérivés de thiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation |
CA3047286A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Oxazine derivatives as beta-secretase inhibitors and methods of use |
CN107576785A (zh) * | 2017-08-25 | 2018-01-12 | 广州市雷德生物科技有限公司 | 一种样本处理液及其应用 |
GB201803010D0 (en) * | 2018-02-26 | 2018-04-11 | Royal Holloway & Bedford New College | Neurodegenerative disorders |
CN111518793A (zh) * | 2020-05-20 | 2020-08-11 | 谭骏 | 年轻人血源APPα-分泌酶在阿尔茨海默病中的应用 |
CN114480494B (zh) * | 2022-02-10 | 2024-07-05 | 中国科学技术大学 | 蛋白探针以及其在检测bace1活性中的应用 |
CN116829956A (zh) * | 2023-02-28 | 2023-09-29 | 湖南乾康科技有限公司 | 用于检测蛋白生物标志物组的抗体在制备诊断ad、mci和其它类型老年痴呆的试剂盒中的用途 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5200339A (en) | 1990-08-17 | 1993-04-06 | Abraham Carmela R | Proteases causing abnormal degradation of amyloid β-protein precursor |
US5292652A (en) | 1990-10-05 | 1994-03-08 | Athena Neurosciences, Inc. | Amyloidin protease and uses thereof |
ATE286971T1 (de) | 1991-01-21 | 2005-01-15 | Elan Pharm Inc | Prüfung und modell für alzheimers-krankheit |
US5604131A (en) * | 1992-01-07 | 1997-02-18 | Athena Neurosciences, Inc. | cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions |
TW327194B (en) * | 1992-05-01 | 1998-02-21 | American Cyanamid Co | Novel amyloid precursor proteins and methods of using same |
IL105793A0 (en) | 1992-05-28 | 1993-09-22 | Lilly Co Eli | Protease and related dna compounds |
US5455169A (en) * | 1992-06-04 | 1995-10-03 | Alzheimer's Institute Of America, Inc. | Nucleic acids for diagnosing and modeling Alzheimer's disease |
US5837672A (en) | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US5605811A (en) * | 1992-10-26 | 1997-02-25 | Athena Neurosciences, Inc. | Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein |
JPH08508464A (ja) | 1992-12-16 | 1996-09-10 | ベイヤー コーポレイション | カテプシンdはアルツハイマー病におけるアミロイド生成プロテアーゼである |
EP0608546A3 (en) * | 1992-12-22 | 1995-09-27 | Takeda Chemical Industries Ltd | Glia activating factor (gaf), antibodies against it and their uses. |
EP0683234B2 (en) | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antibody against beta-amyloid or their derivative and use thereof |
CA2174429C (en) | 1993-10-27 | 2011-08-30 | Lisa C. Mcconlogue | Transgenic animals harboring app allele having swedish mutation |
WO1996006927A1 (en) | 1994-09-01 | 1996-03-07 | Merck & Co., Inc. | Transgenic animal expressing a familial form of human amyloid precursor protein |
CA2217492A1 (en) | 1995-04-04 | 1996-10-10 | Edward Marion Johnstone | Amyloid precursor protein protease |
US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
US6221645B1 (en) | 1995-06-07 | 2001-04-24 | Elan Pharmaceuticals, Inc. | β-secretase antibody |
WO1996040885A2 (en) * | 1995-06-07 | 1996-12-19 | Athena Neurosciences, Inc. | β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION |
DE19641180A1 (de) | 1996-09-24 | 1998-03-26 | Schering Ag | Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung |
WO1998021589A1 (en) | 1996-11-15 | 1998-05-22 | The Trustees Of The University Of Pennsylvania | Screening for modulators of amyloid processing |
AU1684097A (en) * | 1996-12-11 | 1998-07-03 | Athena Neurosciences, Inc. | Beta-secretase isolated from human 293 cells |
EP0848062A3 (en) * | 1996-12-14 | 2000-07-05 | Smithkline Beecham Corporation | Aspartic protease ASP1 |
GB9626022D0 (en) | 1996-12-14 | 1997-01-29 | Smithkline Beecham Plc | Novel compounds |
GB9701684D0 (en) * | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
GB9721094D0 (en) * | 1997-10-03 | 1997-12-03 | Unilever Plc | Autophobic hairspray compositions |
ATE440951T1 (de) | 1997-12-17 | 2009-09-15 | Serono Genetics Inst Sa | Verlängerte cdns, die für sekretierte proteine kodieren |
AU1726199A (en) * | 1997-12-31 | 1999-07-19 | Chiron Corporation | Metastatic cancer regulated gene |
DK1490386T3 (da) * | 1998-03-10 | 2008-12-15 | Genentech Inc | Nyt polypeptid og nukleinsyrer kodende for dette |
HUP0104022A2 (hu) | 1998-06-05 | 2002-03-28 | Aventis Pharma S.A. | Béta-szekretáz típusú aktivitással rendelkező polipeptidek |
US6699671B1 (en) | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
US6844148B1 (en) | 1998-09-24 | 2005-01-18 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
KR100768381B1 (ko) | 1998-09-24 | 2007-10-18 | 파마시아 앤드 업존 캄파니 엘엘씨 | 알츠하이머병 세크레타제 |
US6245884B1 (en) | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
US6313268B1 (en) | 1998-10-16 | 2001-11-06 | Vivian Y. H. Hook | Secretases related to Alzheimer's dementia |
GB2364059B (en) * | 1999-02-10 | 2004-01-14 | Elan Pharm Inc | Beta-Secretase enzyme compositions and methods |
DE19910108C2 (de) | 1999-03-08 | 2001-02-22 | Falk Fahrenholz | Zellen, die ein Amyloidvorläuferprotein und eine alpha-Sekretase coexprimieren, ein Testverfahren zur Identifikation alpha-Sekretase-aktiver Substanzen sowie eines zur Identifikation weiterer Sekretasen, ein Testverfahren zur Bestimmung der Anfälligkeit gegenüber Morbus Alzheimer und Verwendung von Nukleinsäuren, die für eine alpha-Sekretase codieren, für die Gentherapie |
WO2000058479A1 (en) | 1999-03-26 | 2000-10-05 | Amgen Inc. | Beta secretase genes and polypeptides |
WO2000068266A1 (en) | 1999-05-11 | 2000-11-16 | Eli Lilly And Company | Amyloid precursor protein protease and related nucleic acid compounds |
US7087399B1 (en) | 1999-05-13 | 2006-08-08 | Scios, Inc. | β-secretase and modulation of β-secretase activity |
US6545127B1 (en) | 1999-06-28 | 2003-04-08 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
GB9924957D0 (en) | 1999-10-21 | 1999-12-22 | Smithkline Beecham Plc | Novel treatment |
GB9925136D0 (en) | 1999-10-22 | 1999-12-22 | Smithkline Beecham Plc | Novel treatment |
US6361975B1 (en) | 1999-11-16 | 2002-03-26 | Smithkline Beecham Corporation | Mouse aspartic secretase-2(mASP-2) |
US6291223B1 (en) | 1999-11-23 | 2001-09-18 | Smithkline Beecham Corporation | Mouse aspartic secretase-1 (mASP1) |
-
1999
- 1999-09-23 KR KR1020047015171A patent/KR100768381B1/ko not_active IP Right Cessation
- 1999-09-23 NZ NZ527053A patent/NZ527053A/xx not_active IP Right Cessation
- 1999-09-23 US US09/806,194 patent/US6835565B1/en not_active Expired - Fee Related
- 1999-09-23 SG SG200301440A patent/SG113454A1/en unknown
- 1999-09-23 EA EA200100387A patent/EA009216B1/ru not_active IP Right Cessation
- 1999-09-23 CN CNB99811202XA patent/CN1198936C/zh not_active Expired - Fee Related
- 1999-09-23 CZ CZ2001966A patent/CZ2001966A3/cs unknown
- 1999-09-23 PT PT99948189T patent/PT1115874E/pt unknown
- 1999-09-23 KR KR1020067023390A patent/KR20060126626A/ko not_active Application Discontinuation
- 1999-09-23 CN CNB2003101196656A patent/CN1300320C/zh not_active Expired - Fee Related
- 1999-09-23 KR KR1020047015172A patent/KR100691601B1/ko not_active IP Right Cessation
- 1999-09-23 KR KR1020077000411A patent/KR20070013361A/ko not_active Application Discontinuation
- 1999-09-23 BR BR9913920-0A patent/BR9913920A/pt not_active Application Discontinuation
- 1999-09-23 DK DK99948189T patent/DK1115874T3/da active
- 1999-09-23 AU AU61418/99A patent/AU772812C/en not_active Ceased
- 1999-09-23 SK SK390-2001A patent/SK3902001A3/sk unknown
- 1999-09-23 CN CNA2003101196641A patent/CN1502696A/zh active Pending
- 1999-09-23 HU HU0103838A patent/HUP0103838A3/hu unknown
- 1999-09-23 DE DE69940265T patent/DE69940265D1/de not_active Expired - Lifetime
- 1999-09-23 ES ES99948189T patent/ES2318902T3/es not_active Expired - Lifetime
- 1999-09-23 KR KR1020047015170A patent/KR100866676B1/ko not_active IP Right Cessation
- 1999-09-23 KR KR1020017003744A patent/KR100839284B1/ko not_active IP Right Cessation
- 1999-09-23 TR TR2002/00662T patent/TR200200662T2/xx unknown
- 1999-09-23 WO PCT/US1999/020881 patent/WO2000017369A2/en active Application Filing
- 1999-09-23 CA CA002343004A patent/CA2343004A1/en not_active Abandoned
- 1999-09-23 EP EP99948189A patent/EP1115874B1/en not_active Expired - Lifetime
- 1999-09-23 PL PL348629A patent/PL205294B1/pl not_active IP Right Cessation
- 1999-09-23 NZ NZ510708A patent/NZ510708A/en not_active IP Right Cessation
- 1999-09-23 KR KR1020067020982A patent/KR20060111905A/ko not_active Application Discontinuation
- 1999-09-23 TR TR2001/01484T patent/TR200101484T2/xx unknown
- 1999-09-23 AT AT99948189T patent/ATE420185T1/de active
- 1999-09-23 KR KR1020067025867A patent/KR20070004143A/ko active IP Right Grant
- 1999-09-23 JP JP2000574268A patent/JP2002526081A/ja active Pending
- 1999-09-23 CN CNA2003101196637A patent/CN1502692A/zh active Pending
- 1999-09-23 TR TR2006/01231T patent/TR200601231T2/xx unknown
-
2001
- 2001-03-22 IS IS5905A patent/IS5905A/is unknown
- 2001-03-22 ZA ZA200102387A patent/ZA200102387B/en unknown
- 2001-03-22 IL IL142207A patent/IL142207A/en not_active IP Right Cessation
- 2001-03-23 NO NO20011505A patent/NO20011505L/no not_active Application Discontinuation
-
2002
- 2002-05-31 HK HK02104092.7A patent/HK1042730B/zh not_active IP Right Cessation
-
2004
- 2004-07-14 HK HK04105123A patent/HK1062187A1/xx not_active IP Right Cessation
- 2004-08-04 AU AU2004203588A patent/AU2004203588B2/en not_active Ceased
- 2004-09-14 US US10/940,867 patent/US7812123B2/en not_active Expired - Lifetime
-
2007
- 2007-03-20 IL IL182070A patent/IL182070A0/en not_active IP Right Cessation
- 2007-12-12 JP JP2007320832A patent/JP2008113665A/ja not_active Withdrawn
-
2009
- 2009-02-18 CY CY20091100178T patent/CY1111006T1/el unknown
- 2009-06-10 JP JP2009139454A patent/JP2009201517A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1115874T3 (da) | Alzheimer's sygdom-sekretase | |
WO2001049097A3 (en) | Alzheimer's disease secretase, app substrates therefor, and uses therefor | |
TW200745552A (en) | HU-ASP 1 protease substrate and uses thereof | |
DE69636866D1 (en) | Reverse "two-hybrid"-systeme | |
MY120693A (en) | Human bikunin | |
CA2263713A1 (en) | Lyophilization of cultured human cells to preserve rna and dna | |
PT1025245E (pt) | Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes | |
DE69928395D1 (de) | Cyclin-e2 proteine und dafür kodierende gene | |
NO20003880D0 (no) | Transfekterende midler som er sensitive overfor reduserende betingelser, farmasøytiske preparater inneholdende disse samt deres anvendelser | |
DE60044038D1 (de) | Xylosyltransferase und isoformen | |
AU2001238064A1 (en) | 18477, a human protein kinase and uses therefor | |
WO1999047673A3 (en) | Isolated mammalian membrane protein genes and related reagents | |
WO1999022005A3 (en) | Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor | |
WO2002074921A3 (en) | Methods for isolating proteins expressed by dendritic cells | |
WO2001066709A3 (en) | Sphingomyelinase enzymes and uses relating thereto | |
WO1999001567A3 (en) | Methods and compositions for a deubiquitinating enzyme and variants thereof | |
CY1110496T1 (el) | Σεκρεταση νοσου alzheimer, υποστρωματα app αυτης, και χρησεις αυτης | |
GB2289125A (en) | Methods of assaying data-repairing enzymes and their alkylated derivatives | |
ECSP003672A (es) | Secretasa en la enfermedad de alzheimer, substratos de la app y sus usos | |
DK1141337T3 (da) | Gram-positive bakterier, som mangler HtrA-proteaseaktivitet, samt deres anvendelser | |
TH51992A (th) | ซีครีเทสของโรคแอลซ์ไฮม์เมอร์ app สับสเตรทของมัน และการใช้งานของมัน | |
AU3354199A (en) | Prostate derived serine protease (pdsp) protein and nucleic acid molecules and uses therefor | |
TH51992B (th) | ซีครีเทสของโรคแอลซ์ไฮม์เมอร์ app สับสเตรทของมัน และการใช้งานของมัน | |
ECSP993285A (es) | Sintesis recombinante de beta lipotropina y otros peptidos |